Insulet, a U.S.-based diabetes device manufacturer, has officially opened a new manufacturing facility in Johor Bahru, Malaysia, marking a significant milestone in a USD 200 million investment. Spanning 400,000 square feet, the new plant is twice the size of the company’s production facility in Acton, Massachusetts, and is designed to meet the growing regional demand for its products.
Situated at the southern tip of the Malay Peninsula, just north of Singapore, Insulet’s new facility currently employs over 350 full-time workers, with plans to expand the workforce to more than 1,000 in the coming years. The establishment of this state-of-the-art manufacturing facility aligns with Insulet’s strategy to meet the increasing demand for its Omnipod 5, the first and only tubeless automated insulin delivery system in the U.S. By positioning itself in Malaysia, Insulet aims to ensure that customers have uninterrupted access to its products from this strategically located hub. The new facility is set to enhance the company’s global operational capabilities and bolster supply chain resilience.
In addition to its operational goals, the new facility incorporates several sustainable design features, aiming to achieve both Green Building Index (GBI) certification and Leadership in Energy and Environmental Design (LEED) Silver certification. Key sustainable elements include over 5,700 solar panels that supply approximately 15% of the building’s power requirements and an underground rainwater harvesting system designed to fulfill 30% of the landscaping water needs. The facility also utilizes energy-efficient equipment and construction materials to mitigate heat island effects, emphasizing Insulet’s commitment to environmental responsibility.
(Sources: FiercePharma; QuantisNow)
